All In Biotech

Drug Trial Radar · NCT06783829

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4394 Injection in Subjects With Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jan 22, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • SHR4394Drug

    SHR4394

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: 3 weeks.
  2. Maximal tolerable dose (MTD)Time frame: 3 weeks.
  3. Adverse events (AEs)Time frame: Screening up to study completion, an average of 1 year.
  4. Recommended phase II dose (RP2D)Time frame: Screening up to study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.